The FAAH inhibitor URB597 efficiently reduces tyrosine hydroxylase expression through CB1- and FAAH-independent mechanisms

British Journal of Pharmacology

Volumn 169, Issue 4, 2013, Pages 794-807

  Bosier, Barbara ^a   Muccioli, Giulio G ^a   Lambert, Didier M ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Abn CBD; cannabidiol; carbamate; CB1 independent mechanism; dopamine; endocannabinoid; MAPK; off target; PF750; tyrosine hydroxylase promoter

Indexed keywords

ANANDAMIDE; CANNABIDIOL SENSITIVE RECEPTOR; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; FATTY ACID AMIDASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN LEVEL; CATECHOLAMINE RELEASE; CELL ASSAY; CONTROLLED STUDY; DEPRESSION; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME INHIBITION; ENZYME REGULATION; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS; RECEPTOR UPREGULATION; REPORTER GENE; SIGNAL TRANSDUCTION;

AMIDOHYDROLASES; ANIMALS; ANIMALS, OUTBRED STRAINS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BENZAMIDES; CANNABIDIOL; CANNABINOID RECEPTOR ANTAGONISTS; CARBAMATES; CELL LINE, TUMOR; CORPUS STRIATUM; DOPAMINERGIC NEURONS; ENDOCANNABINOIDS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENES, REPORTER; HIPPOCAMPUS; MICE; NERVE TISSUE PROTEINS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PROMOTER REGIONS, GENETIC; RECEPTOR, CANNABINOID, CB1; TYROSINE 3-MONOOXYGENASE;

EID: 84878270506     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02208.x     Document Type: Article

References (62)

1. Ahn K, Johnson DS, Fitzgerald LR, Liimatta M, Arendse A, Stevenson T, et al. (2007). Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry 46: 13019-13030.
2. Alexander SPH, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edn. Br J Pharmacol 164 (Suppl. 1): S1-S324.
3. Alhouayek M, Lambert DM, Delzenne NM, Cani PD, Muccioli GG, (2011). Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. FASEB J 25: 2711-2721.
4. Blankman JL, Simon GM, Cravatt BF, (2007). A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14: 1347-1356.
5. Bonnin A, Fernandez-Ruiz JJ, Martin M, Rodriguez de Fonseca F, Hernandez ML, Ramos JA, (1993). delta 9-Tetrahydrocannabinol affects mesolimbic dopaminergic activity in the female rat brain: interactions with estrogens. J Neural Transm Gen Sect 92: 81-95.
6. Bosier B, Tilleux S, Najimi M, Lambert DM, Hermans E, (2007). Agonist selective modulation of tyrosine hydroxylase expression by cannabinoid ligands in a murine neuroblastoma cell line. J Neurochem 102: 1996-2007.
7. Bosier B, Hermans E, Lambert DM, (2009). Concomitant activation of adenylyl cyclase suppresses the opposite influences of CB(1) cannabinoid receptor agonists on tyrosine hydroxylase expression. Biochemistry 77: 216-227.
8. Cachope R, Mackie K, Triller A, O'Brien J, Pereda AE, (2007). Potentiation of electrical and chemical synaptic transmission mediated by endocannabinoids. Neuron 56: 1034-1047.
9. Cadogan AK, Alexander SP, Boyd EA, Kendall DA, (1997). Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J Neurochem 69: 1131-1137.
10. Calignano A, La Rana G, Piomelli D, (2001). Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol 419: 191-198.
11. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949.
12. Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, (2005). Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313: 352-358.
13. Gelman L, Michalik L, Desvergne B, Wahli W, (2005). Kinase signalling cascades that modulate peroxisome proliferator-activated receptors. Curr Opin Cell Biol 17: 216-222.
14. Gerdeman G, Lovinger DM, (2001). CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 85: 468-471.
15. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, et al. (2005). Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A 102: 18620-18625.
16. González S, Mena MA, Lastres-Becker I, Serrano A, de Yébenes JG, Ramos JA, et al. (2005). Cannabinoid CB(1) receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice. Brain Res 1046: 195-206.
17. Hao S, Avraham Y, Mechoulam R, Berry EM, (2000). Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 392: 147-156.
18. Huang CC, Lo SW, Hsu KS, (2001). Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J Physiol 532: 731-748.
19. Jacobsson SO, Fowler CJ, (2001). Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide. Br J Pharmacol 132: 1743-1754.
20. Járai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, et al. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A 96: 14136-14141.
21. Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW, (2006). Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147: 281-288.
22. Jhaveri MD, Richardson D, Robinson I, Garle MJ, Patel A, Sun Y, et al. (2008). Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. Neuropharmacology 55: 85-93.
23. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 76-81.
24. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
25. Kreitzer AC, Malenka RC, (2007). Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 445: 643-647.
26. de Lago E, de Miguel R, Lastres-Becker I, Ramos JA, Fernandez-Ruiz J, (2004). Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. Brain Res 1007: 152-159.
27. Lee G, Elwood F, McNally J, Weiszmann J, Lindstrom M, Amaral K, et al. (2002). T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem 277: 19649-19657.
28. Leung D, Hardouin C, Boger DL, Cravatt BF, (2003). Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat Biotechnol 21: 687-691.
29. Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, et al. (2004). Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311: 441-448.
30. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, et al. (2005). The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67: 15-19.
31. Long JZ, LaCava M, Jin X, Cravatt BF, (2011). An anatomical and temporal portrait of physiological substrates for fatty acid amide hydrolase. J Lipid Res 52: 337-344.
32. Luchicchi A, Lecca S, Carta S, Pillolla G, Muntoni AL, Yasar S, et al. (2010). Effects of fatty acid amide hydrolase inhibition on neuronal responses to nicotine, cocaine and morphine in the nucleus accumbens shell and ventral tegmental area: involvement of PPAR-alpha nuclear receptors. Addict Biol 15: 277-288.
33. Maione S, Bisogno T, DeNovellis V, Palazzo E, Cristino L, Valenti M, et al. (2006). Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther 316: 969-982.
34. Maldonado R, Valverde O, Berrendero F, (2006). Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29: 225-232.
35. Marinelli S, Di Marzo V, Berretta N, Matias I, Maccarrone M, Bernardi G, et al. (2003). Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J Neurosci 23: 3136-3144.
36. Mazzola C, Medalie J, Scherma M, Panlilio LV, Solinas M, Tanda G, et al. (2009). Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors. Learn Mem 16: 332-337.
37. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
38. Melis M, Pillolla G, Luchicchi A, Muntoni AL, Yasar S, Goldberg SR, et al. (2008). Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. J Neurosci 28: 13985-13994.
39. Muccioli GG, (2010). Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discov Today 15: 474-483.
40. Muccioli GG, Stella N, (2008). An optimized GC-MS method detects nanomolar amounts of anandamide in mouse brain. Anal Biochem 373: 220-228.
41. Muccioli GG, Xu C, Odah E, Cudaback E, Cisneros JA, Lambert DM, et al. (2007). Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells. J Neurosci 27: 2883-2889.
42. Muccioli GG, Labar G, Lambert DM, (2008). CAY10499, a novel monoglyceride lipase inhibitor evidenced by an expeditious MGL assay. Chembiochem 9: 2704-2710.
43. Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, Mechoulam R, Drucker-Colín R, (2006). Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Lett 580: 4337-4345.
44. Murillo-Rodríguez E, Vázquez E, Millán-Aldaco D, Palomero-Rivero M, Drucker-Colin R, (2007). Effects of the fatty acid amide hydrolase inhibitor URB597 on the sleep-wake cycle, c-Fos expression and dopamine levels of the rat. Eur J Pharmacol 562: 82-91.
45. Niforatos W, Zhang XF, Lake MR, Walter KA, Neelands T, Holzman TF, et al. (2007). Activation of TRPA1 channels by the fatty acid amide hydrolase inhibitor 3′-carbamoylbiphenyl-3-yl cyclohexylcarbamate (URB597). Mol Pharmacol 71: 1209-1216.
46. Offertáler L, Mo FM, Bátkai S, Liu J, Begg M, Razdan RK, et al. (2003). Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 63: 699-705.
47. Oka S, Nakajima K, Yamashita A, Kishimoto S, Sugiura T, (2007). Identification of GPR55 as a lysophosphatidylinositol receptor. Biochemistry 362: 928-934.
48. Page ME, Oropeza VC, Sparks SE, Qian Y, Menko AS, Van Bockstaele EJ, (2007). Repeated cannabinoid administration increases indices of noradrenergic activity in rats. Pharmacol Biochem Behav 86: 162-168.
49. Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, et al. (2006). Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 12: 21-38.
50. Romero J, de Miguel R, Garcia-Palomero E, Fernandez-Ruiz JJ, Ramos JA, (1995a). Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. Brain Res 694: 223-232.
51. Romero J, Garcia L, Cebeira M, Zadrozny D, Fernandez-Ruiz JJ, Ramos JA, (1995b). The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons. Life Sci 56: 2033-2040.
52. Rubino T, Realini N, Castiglioni C, Guidali C, Vigano D, Marras E, et al. (2008). Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex 18: 1292-1301.
53. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 1092-1101.
54. Sagar DR, Kendall DA, Chapman V, (2008). Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. Br J Pharmacol 155: 1297-1306.
55. Scherma M, Panlilio LV, Fadda P, Fattore L, Gamaleddin I, Le Foll B, et al. (2008). Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3′-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats. J Pharmacol Exp Ther 327: 482-490.
56. Seimandi M, Lemaire G, Pillon A, Perrin A, Carlavan I, Voegel JJ, et al. (2005). Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands. Anal Biochem 344: 8-15.
57. Solinas M, Justinova Z, Goldberg SR, Tanda G, (2006). Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem 98: 408-419.
58. Sun YX, Tsuboi K, Zhao LY, Okamoto Y, Lambert DM, Ueda N, (2005). Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. Biochim Biophys Acta 1736: 211-220.
59. Tarzia G, Duranti A, Tontini A, Piersanti G, Mor M, Rivara S, et al. (2003). Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J Med Chem 46: 2352-2360.
60. Tsuboi K, Zhao LY, Okamoto Y, Araki N, Ueno M, Sakamoto H, et al. (2007). Predominant expression of lysosomal N-acylethanolamine-hydrolyzing acid amidase in macrophages revealed by immunochemical studies. Biochim Biophys Acta 1771: 623-632.
61. Walter L, Franklin A, Witting A, Moller T, Stella N, (2002). Astrocytes in culture produce anandamide and other acylethanolamides. J Biol Chem 277: 20869-20876.
62. Zhang D, Saraf A, Kolasa T, Bhatia P, Zheng GZ, Patel M, et al. (2007). Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets. Neuropharmacology 52: 1095-1105.